
|Articles|November 21, 2007
Schizophrenia drug gains new indication for maintenance treatment
Seroquel XR from AstraZeneca has gained a new indication: for maintenance treatment of schizophrenia in adults
Advertisement
AstraZeneca's Seroquel XR (quetiapine fumarate) Extended-Release Tablets have been approved for maintenance treatment of schizophrenia in adult patients. This follows an earlier approval, in May, for acute treatment of schizophrenia in adult patients. The Wilmington, Del., firm explained that schizophrenia patients often suffer relapses, so Seroquel XR will provide a new long-term treatment option for them.
To go to the Drug Topics homepage,
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Embedded Pharmacists Are Vital Yet Underutilized in Diabetes Care
2
Executive Order Calls for Realignment of Childhood Vaccines
3
The Prodigious PBM Pivot: How Supply Chain Entities Will Move Forward After CAA 2026
4
Q&A: Pharmacists Can Address ADA Standards Across All Settings
5





























































